Source comparison
MOTS-c vs Humanin vs Standard Metabolic Peptides: Functional Comparison
MOTS-c AMPK activation, nuclear translocation under stress Yes. Encoded in 12S rRNA gene 30–40% improvement in rodent models, measurable human effects Phase I complete, Phase II ongoing The only MDP with direct AMPK-independent metabolic regulation proven in h
This comparison does not assign a generated winner or score.
- MOTS-c
- AMPK activation, nuclear translocation under stress
- Yes. Encoded in 12S rRNA gene
- 30–40% improvement in rodent models, measurable human effects
- Phase I complete, Phase II ongoing
- The only MDP with direct AMPK-independent metabolic regulation proven in human trials
- Humanin
- Neuroprotection, anti-apoptotic signalling via STAT3
- Yes. Encoded in 16S rRNA gene
- Minimal direct effect, secondary through inflammation reduction
- Preclinical and observational human data
- Primarily protective rather than metabolic. Addresses cell survival under stress
- GLP-1 agonists (e.g., semaglutide)
- Incretin mimetic, slows gastric emptying, suppresses appetite
- No. Synthetic peptide analogue
- Indirect via weight loss and reduced caloric intake
- FDA-approved, extensive Phase III data
- Pharmacological appetite suppression. Fundamentally different mechanism from mitochondrial signalling
- Metformin
- Complex I inhibition, secondary AMPK activation
- No. Small molecule biguanide
- 10–15% improvement via AMPK and reduced hepatic glucose output
- Established first-line therapy for T2D
- Requires energy depletion to activate AMPK, unlike MOTS-c which bypasses this step
- AICAR
- Direct AMPK activator (AMP mimetic)
- No. Synthetic nucleoside analogue
- Comparable to MOTS-c in magnitude but through different upstream pathway
- Research use only, not approved for human therapy
- MOTS-c offers similar metabolic outcomes without mimicking AMP. Potentially safer long-term profile